Skip to content

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515286-34-00
Acronym
ALN-F1202-HV-2412
Enrollment
56
Registered
2025-01-31
Start date
2025-03-06
Completion date
Unknown
Last updated
2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Interventions

None listed

Sponsors

Regeneron Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026